Nanodose Therapeutics is headquartered in Albany, NY and is a privately held pharmaceutical Company formed in 2016 as a spinout from Beech Tree Labs, Inc. The company was founded with the goal to commercialize two pharmaceutical products that Beech Tree developed – oxidized streptolysin O (“NanoSLO”) and a series of products built around NanoSLO.  Since that time, Nanodose Therapeutics has been strengthening our discovery platform with significant advances through genetic testing, animal model evaluations, FDA feedback and preparation for formal patient clinical trials.

 

These products utilize cellular signaling to impact several medical conditions – typically those that involve disorders of the central nervous system and brain – such as chronic traumatic brain injury, Alzheimer’s disease, stroke and others.
​

The Company’s leadership includes a number of current and former biotech CEOs and embodies over 150 years of combined experience in building successful enterprises.